stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.78
1.25
−4.80%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) EBITDA
Caris Life Sciences,�Inc.'s EBITDA for fiscal 2025 was $80.5M, compared with −$201.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $180.0M. Caris Life Sciences,�Inc. ranks 22nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $80.5M | — |
| FY2024 | −$201.2M | — |
| FY2023 | −$265.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $33.8M | 160.30% |
| Mar 2026 | $13.0M | (86.10%) |
| Dec 2025 | $93.3M | 133.41% |
| Sep 2025 | $40.0M | — |
| 4 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CAI
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement